208 related articles for article (PubMed ID: 32964819)
21. SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension.
Farrow KN; Lakshminrusimha S; Czech L; Groh BS; Gugino SF; Davis JM; Russell JA; Steinhorn RH
Am J Physiol Lung Cell Mol Physiol; 2010 Jul; 299(1):L109-16. PubMed ID: 20400523
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
23. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Andric SA; Janjic MM; Stojkov NJ; Kostic TS
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
[TBL] [Abstract][Full Text] [Related]
24. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
26. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
27. Acute pulmonary hypertension in infants and children: cGMP-related drugs.
Fraisse A; Wessel DL
Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S37-40. PubMed ID: 20216161
[TBL] [Abstract][Full Text] [Related]
28. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
[TBL] [Abstract][Full Text] [Related]
29. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
Hemnes AR; Champion HC
Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.
Leibovitch L; Matok I; Paret G
Drugs; 2007; 67(1):57-73. PubMed ID: 17209664
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Steiner MK; Preston IR; Klinger JR; Hill NS
Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
[TBL] [Abstract][Full Text] [Related]
32. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
33. Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension.
Ueda Y; Johnson LR; Ontiveros ES; Visser LC; Gunther-Harrington CT; Stern JA
Sci Rep; 2019 May; 9(1):6899. PubMed ID: 31053768
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
Moreland RB; Goldstein I; Traish A
Life Sci; 1998; 62(20):PL 309-18. PubMed ID: 9600334
[TBL] [Abstract][Full Text] [Related]
35. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.
Lepore JJ; Maroo A; Bigatello LM; Dec GW; Zapol WM; Bloch KD; Semigran MJ
Chest; 2005 May; 127(5):1647-53. PubMed ID: 15888841
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
Boydens C; Pauwels B; Vanden Daele L; Van de Voorde J
J Sex Med; 2017 Apr; 14(4):502-509. PubMed ID: 28258955
[TBL] [Abstract][Full Text] [Related]
37. [Role of NO-cGMP-PKG axis in pulmonary arterial hypertension].
Watanabe H
Nihon Yakurigaku Zasshi; 2022; 157(4):221-225. PubMed ID: 35781448
[TBL] [Abstract][Full Text] [Related]
38. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Magee AG; Makhecha S; Bentley S
Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
[TBL] [Abstract][Full Text] [Related]
39. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells.
Farrow KN; Groh BS; Schumacker PT; Lakshminrusimha S; Czech L; Gugino SF; Russell JA; Steinhorn RH
Circ Res; 2008 Feb; 102(2):226-33. PubMed ID: 17991881
[TBL] [Abstract][Full Text] [Related]
40. Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Karakhanova S; Yang Y; Link J; Soltek S; von Ahn K; Umansky V; Werner J; Bazhin AV
Mol Immunol; 2013 Dec; 56(4):649-59. PubMed ID: 23911424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
